Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03936556 · ClinicalTrials.gov registry record · Phase 4
A Clinical Study to Assess the Effects of a Stannous Fluoride Dentifrice on Plaque and Gingivitis
A Phase 4 study, sponsored by Procter and Gamble.
- Completed
- Registry status
- Phase 4
- Development phase
- 84
- Enrollment target
NCT03936556: Completed Phase 4 study, sponsored by Procter and Gamble.
NCT03936556 is a Phase 4 study that has completed, run by Procter and Gamble. The registered enrollment target is 84 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03936556, a Phase 4 study, has completed, sponsored by Procter and Gamble.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 84 participants
- Enrollment target
Study Summary
The objective of this clinical study is to assess the effects of a 0.454% stannous fluoride dentifrice on gingivitis and plaque after 3 months when compared to a negative control.
Primary Outcome
Löe-Silness Gingivitis Evaluation is a validated assessment of gingival health looking at inflammation and bleeding based on a 4 point range 0 (normal gingiva) to 3 (severe inflammation).
Interventions
- DRUG Marketed Cavity Protection Toothpaste
- DRUG Marketed toothpaste
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2018-02-25 |
| Est. Completion | 2018-06-03 |
| Phase | Phase 4 |
What the finished NCT03936556 record still lists
NCT03936556 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 2 interventions - of which Marketed Cavity Protection Toothpaste is the first listed.
NCT03936556 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03936556 about?
NCT03936556 is a clinical study titled "A Clinical Study to Assess the Effects of a Stannous Fluoride Dentifrice on Plaque and Gingivitis". The objective of this clinical study is to assess the effects of a 0.454% stannous fluoride dentifrice on gingivitis and plaque after 3 months when compared to a negative control.
What is the current status of trial NCT03936556?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 84 participants. The study started on 2018-02-25. Estimated completion is 2018-06-03.
What interventions are being tested in trial NCT03936556?
The interventions under investigation include: Marketed Cavity Protection Toothpaste (DRUG), Marketed toothpaste (DRUG).
Who is sponsoring clinical trial NCT03936556?
This trial is sponsored by Procter and Gamble, which has 70 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03936556's enrollment target sits among peer trials
84 929th of 2000 higher than 1,064 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI